Intra-articular polynucleotide,
does it really help with Improved pain and function in knee osteoarthritis?
research showsThe grade is C. A 90-participant trial analyzed 82 completers and favored polynucleotide for 16-week weight-bearing pain, but a 60-participant trial funded by the same manufacturer found no significant between-group difference among 47 completers. The small active-control evidence lacks nonmanufacturer confirmation, giving C with 46 points.
ads claimThe evidence does not establish cartilage regeneration or reliably longer benefit than hyaluronic acid. It supports only a short-term pain difference in small trials, with uncertain function and durability.
Useful facts when choosing a product
- The pivotal trial compared three weekly intra-articular PN injections with conventional or crosslinked hyaluronic acid.
- The primary efficacy analysis used 82 completers rather than all 90 randomized participants; a supportive imputed analysis included 83.
- Verdict 1818 is D with 28 points for periocular cosmetic skin injections, not intra-articular treatment of knee pain.
Chamgap Semantic Classification Code
Candidate index · review held
M.intra-articular-polynucleotide-injection.intraarticular.pain-and-function-in-knee-osteoarthritis.improve.MULTIMedicinal interventions > Intra-articular polynucleotide injection > Intra-articular > pain and function in knee osteoarthritis > Improvement claim > Multiple: primary unresolved
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Both the positive and null trials were small product studies supported by Pharma Research Products. They used active hyaluronic-acid comparators without placebo, and no nonmanufacturer confirmatory trial was identified. The pivotal defects are active control without placebo and the small 90-randomized, 82-completer analysis.
Why this is classified as C (46)
Small positive and null trials shared manufacturer funding, with no placebo or nonmanufacturer confirmation, giving C with 46 points.
Counterpoint. C does not mean no effect; it means a large independent placebo-controlled trial has not established the size and durability of benefit.
Rejudgment record. Cross-check applied — One small manufacturer-funded active-control trial was positive, but a second same-manufacturer trial was null and nonmanufacturer confirmation is absent
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E~ | Statistically positive but below the threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved weight-bearing pain at 16 weeks | C | Positive in an 82-completer active-control analysis with very wide intervals. |
| Improved function | D | The 2019 synthesis found no functional advantage over hyaluronic acid. |
| Durable long-term pain superiority | D | Consistent superiority beyond four months has not been established. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Moon, Kim et al. 2023 multicenter trial | Randomized double-blind three-arm active-control trial | 90 randomized; 82 in the primary completer efficacy analysis | Funded by PN manufacturer Pharma Research | Between-group difference in 16-week weight-bearing VAS change, the primary endpoint | PN versus conventional HA -17.6 mm, 95% CI -35.1 to -0.1, adjusted P=0.048; versus crosslinked HA -22.4 mm, 95% CI -41.5 to -3.3, adjusted P=0.016. | Pivotal positive but small completer-based active-control trial |
| Kim TW et al. 2023, Scientific Reports 13:9419 | Multicenter double-blind randomized hyaluronic-acid active-control trial | 60 randomized, 30 per arm; 47 completed, 21 versus 26 | Supported by Pharma Research Products | Percentage change in weight-bearing pain at week 16 | -54.0±38.1% versus -42.8±35.8%, P=0.296; other pain and function measures also showed no significant between-group differences. | Null replication trial funded by the same manufacturer |
Receipt — 5 References
All 5 cited sources were verified for existence at the original page (as of 2026-08-01).
Final verification and publication gate: Codex · Evidence date: 2026-08-01 · Corrections: none
Cite this verdict
[Chamgap] Intra-articular polynucleotide x knee osteoarthritis pain and function — Evidence Grade C·46. 5 cited sources checked. Source: https://chamgap.com/en/verdicts/joint-bone/intraarticular-polynucleotide-knee-osteoarthritis-pain-function/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.